Debate: why surgery should remain central in the management of locally advanced (Stage III) non-small-cell lung cancer
{{output}}
Stage III non-small cell lung cancer (NSCLC) comprises a broadly heterogeneous disease with historically poor survival, and treatment decisions must account for both pathophysiology and resectability. Despite conclusions from older trials that questioned the r... ...
